◆英語タイトル:Verona Pharma Plc (VRP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012304
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月14日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company’s lead candidate, RPL554 is a bronchodilator/anti-inflammatory drug which is being developed for a wide range of indications including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma. The company has collaborations with King’s College London McGill University and The University of North Carolina for conducting research and experimental studies and to the fund exploratory studies. The company has operations in North America and the UK. Verona Pharma is headquartered in London, the UK.
Verona Pharma Plc (VRP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Verona Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Verona Pharma Plc, Medical Devices Deals, 2011 to YTD 2017 10
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Verona Pharma Enters into Agreement with European Technology Companies 12
Equity Offering 13
Verona Pharma Announces Exercise of Over-Allotment Option for Public Offering of ADS for USD87.2 Million 13
Verona Pharma Raises USD2 Million in Private Placement of Shares 15
Verona Pharma Raises USD78 Million in Public Offering of Shares 16
Verona Pharma Raises USD63 Million in Private Placement of Units 17
Verona Pharma Raises USD21.7 Million in Private Placement of Shares 20
Verona Pharma Completes Rights Offering Of Shares For US$1.7 Million 21
Verona Pharma Announces Private Placement Of Shares For US$1.3 Million 22
Verona Pharma Prices Private Placement Of Shares For US$2 Million 23
Verona Pharma Announces Private Placement Of Shares For US$8 Million 24
Verona Pharma Completes Private Placement Of Common Stock For US$5 Million 25
Verona Pharma Plc – Key Competitors 26
Verona Pharma Plc – Key Employees 27
Verona Pharma Plc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 07, 2017: Verona Pharma Operational Update and Financial Results for the Third Quarter Ended September 30, 2017 29
Aug 08, 2017: Verona Pharma Interim Results for the Six Months Ended June 30, 2017 31
Feb 27, 2017: Verona Pharma Announces Financial results for the year ended 31 December 2016 32
Sep 13, 2016: Verona Pharma: Interim results for the Six Months Ended 30 June 2016 34
Jun 03, 2016: Verona Pharma Announces Financial results for the year ended 31 December 2015 36
Corporate Communications 38
Apr 03, 2017: Verona Pharma announces new collaborations to develop dry powder and MDI formulations for COPD 38
Apr 03, 2017: Verona Pharma Announces Board Change 39
Mar 31, 2017: Verona Pharma appoints commercial director 40
Sep 26, 2016: Verona Pharma Announces Appointment of CFO 41
Sep 12, 2016: Verona Pharma: Appointment of Vikas Sinha as Non-Executive Director 42
Jan 11, 2016: Verona Pharma Announces Directorate Change 43
Product News 44
05/04/2016: Verona to present clinical data on RPL554 at the ATS International Conference 44
Clinical Trials 45
May 10, 2016: Verona Pharma announces positive results from add-on phase II trial with RPL554 45
Mar 15, 2016: Verona Pharma reports positive results from RPL554 dose-finding study 47
Other Significant Developments 49
Jul 22, 2016: Verona Pharma Announces Result of General Meeting; Appointment of Directors 49
Mar 21, 2016: Verona Pharma: A successful year with significant progress 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Tables
Verona Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Verona Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Verona Pharma Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Verona Pharma Plc, Medical Devices Deals, 2011 to YTD 2017 10
Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Verona Pharma Enters into Agreement with European Technology Companies 12
Verona Pharma Announces Exercise of Over-Allotment Option for Public Offering of ADS for USD87.2 Million 13
Verona Pharma Raises USD2 Million in Private Placement of Shares 15
Verona Pharma Raises USD78 Million in Public Offering of Shares 16
Verona Pharma Raises USD63 Million in Private Placement of Units 17
Verona Pharma Raises USD21.7 Million in Private Placement of Shares 20
Verona Pharma Completes Rights Offering Of Shares For US$1.7 Million 21
Verona Pharma Announces Private Placement Of Shares For US$1.3 Million 22
Verona Pharma Prices Private Placement Of Shares For US$2 Million 23
Verona Pharma Announces Private Placement Of Shares For US$8 Million 24
Verona Pharma Completes Private Placement Of Common Stock For US$5 Million 25
Verona Pharma Plc, Key Competitors 26
Verona Pharma Plc, Key Employees 27
Verona Pharma Plc, Subsidiaries 28